Grant: Collaborative Health Research Projects
University of Victoria
$64,093.00
Antibody-nanoparticle conjugates as molecular imaging agents for solid brain tumour (glioma)
EF 2012-13
Résumé
Glioblastoma multiforme (GBM) (WHO grade IV) is a highly aggressive tumour with distinct
histopathological features including high proliferation, necrosis, and considerable neo-vascularization. GBM
remains one of the most devastating cancers and is among the most common solid tumours in children.
Radiographic and histological evidence have determined that increased tumour vascularity is correlated with
the clinical grade of gliomas. At present, tissue samples are required for absolute classification, from which the
outcome may be predicted and adjuvant therapies, such as radio and/or chemotherapy, may be determined.
Therefore, there is an unmet clinical need to develop a non-invasive method to assess the degree of glioma
vascularity and determine the associated clinical aggressiveness. Such a molecular imaging method could
significantly improve the clinical management of gliomas.
The application of molecular imaging to CNS neoplasms would ensure more accurate diagnosis if an
appropriate targeted contrast agent were developed. Previously in our laboratory, the insulin-like growth
factor-binding protein-7 (IGFBP7) has been discovered to be a highly up-regulated biomarker specific for
GBM vessels and a single domain antibody (sdAbs) that target against IGFBP7 has been developed.
Bioconjugation of sdAbs to magnetic resonance (MR) and near-infrared (NIR) imaging contrast agents is a
novel method that has the potential to provide accurate molecular imaging of GBM vessels in the clinic. MRI is
an advanced 3D non-invasive imaging modality, but the lack of molecular MR imaging contrast agents with
sufficient specificity and high relaxivity, and thus MR contrast sensitivity, is a major impediment.
We propose to make antibody-nanoparticle conjugates, more specifically to make MR molecular imaging
agents consisting of anti-IGFBP7 sdAb targeted FeCo nanoparticles, which are predicted to have a 3 times
stronger magnetic moment than 20 nm SPIO (superparamagnetic iron oxide) thus providing better targeted
tissue contrast. In addition, it has a turn-on near-infrared optical probe.
Programme
Collaborative Health Research Projects
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
398165-2011
Name nom
vanVeggel, Frank
Department département
Chemistry
Organization id
7
Institution établissement
University of Victoria
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2012
Competition year année de concours
2011
Award amount
64093
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
1100
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Health, education and social services
Area of application fr
Santé publique, éducation et services sociaux
Research subject code
6400
Research subject group en
Life sciences research related to human health and disease
Research subject group fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Research subject en
Life sciences research related to human health and disease
Research subject fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Partie
2
Nb partie
3
Application title
Antibody-nanoparticle conjugates as molecular imaging agents for solid brain tumour (glioma)
Keyword
NSERC
Application summary
Glioblastoma multiforme (GBM) (WHO grade IV) is a highly aggressive tumour with distinct
histopathological features including high proliferation, necrosis, and considerable neo-vascularization. GBM
remains one of the most devastating cancers and is among the most common solid tumours in children.
Radiographic and histological evidence have determined that increased tumour vascularity is correlated with
the clinical grade of gliomas. At present, tissue samples are required for absolute classification, from which the
outcome may be predicted and adjuvant therapies, such as radio and/or chemotherapy, may be determined.
Therefore, there is an unmet clinical need to develop a non-invasive method to assess the degree of glioma
vascularity and determine the associated clinical aggressiveness. Such a molecular imaging method could
significantly improve the clinical management of gliomas.
The application of molecular imaging to CNS neoplasms would ensure more accurate diagnosis if an
appropriate targeted contrast agent were developed. Previously in our laboratory, the insulin-like growth
factor-binding protein-7 (IGFBP7) has been discovered to be a highly up-regulated biomarker specific for
GBM vessels and a single domain antibody (sdAbs) that target against IGFBP7 has been developed.
Bioconjugation of sdAbs to magnetic resonance (MR) and near-infrared (NIR) imaging contrast agents is a
novel method that has the potential to provide accurate molecular imaging of GBM vessels in the clinic. MRI is
an advanced 3D non-invasive imaging modality, but the lack of molecular MR imaging contrast agents with
sufficient specificity and high relaxivity, and thus MR contrast sensitivity, is a major impediment.
We propose to make antibody-nanoparticle conjugates, more specifically to make MR molecular imaging
agents consisting of anti-IGFBP7 sdAb targeted FeCo nanoparticles, which are predicted to have a 3 times
stronger magnetic moment than 20 nm SPIO (superparamagnetic iron oxide) thus providing better targeted
tissue contrast. In addition, it has a turn-on near-infrared optical probe.